• Epidemiology, genetics, pathogenesis, and treatment of IBD
• Role of Gut microbiota in health and disease
• Faecal microbiota transplantation and microbial therapeutics

Siew Ng’s research interests focus on the epidemiology, pathogenesis, and management of inflammatory bowel disease (IBD). She has pioneered IBD research in the Asia-Pacific region and beyond, bringing together more than 30 countries and 100 centres to understand the causes and risks of IBD, resulting in a landmark paper published in Nature. Additionally, she has established a longitudinal microbiome cohort of 100K mother-baby for disease prevention. Siew has also transformed microbial signatures into non-invasive diagnostics using novel multi-bacteria technologies for early disease detection related to colorectal cancer, IBD, and autism spectrum disorder. In 2018, she established Asia’s first faecal microbiota transplantation (FMT) research centre, which is now the sole provider of FMT services to Hong Kong public hospitals for recurrent Clostridioides difficile infections. Her FMT MOZAIC™ technology has led to a reduction in hospitalisations and prolonged survival.

Siew Ng is Croucher Professor in Medical Sciences at the Department of Medicine and Therapeutics and New Cornerstone Investigator by Tencent Foundation. She is the Associate Dean (Research) of the Faculty of Medicine, The Chinese University of Hong Kong (CUHK) and Director of the Microbiota I-Center (MagIC) established under InnoHK, an initiative by the Hong Kong SAR Government.

Siew received her Bachelor of Medicine and Surgery degree from the St. Bartholomew’s and the Royal London Hospital School of Medicine and Dentistry, and Doctor of Philosophy degree (PhD) from Imperial College London. In 2009, Siew joined the Faculty of Medicine, CUHK and became a full professor in 2016. Since 2019, she has co-founded two biotech companies, GenieBiome Limited and MicroSigX Biotech Diagnostic Limited, to transform novel microbiome discoveries into effective diagnostics and therapeutics. She currently serves as President of the Hong Kong Society of Gastroenterology and Advisory Board Member of the Asian Organization of Crohn’s and Colitis (AOCC). She is Associate Editor of Gut.

Siew’s research focuses on the epidemiology, pathogenesis, and management of inflammatory bowel disease (IBD). She has pioneered IBD research in the Asia-Pacific region, establishing a significant mother-baby longitudinal microbiome cohort and advancing non-invasive diagnostics for early detection of diseases such as colorectal cancer, IBD, and autism spectrum disorder.

Siew has published over 430 papers in leading international journals, including Nature, Nature Genetics, Nature Medicine, Cell Host & Microbe, and The Lancet. In 2023, ExpertScape recognised her as the top 0.029% world expert in IBD. Additionally, she has been named a Highly Cited Researcher by Clarivate for six consecutive years since 2020 and has been rated as one of the World’s Top 2 % Scientists by Stanford University since 2020.

In recognition of her achievements, Siew was elected to the International Organization for the Study of IBD (IOIBD), an elite group of the top 50 leaders globally. She was elected as a Foreign Member of the Academia Europaea in Clinical & Veterinary Science in 2024 and as a Member of the Hong Kong Academy of Sciences in 2025. Notably, she was the first female clinician-scientist to be selected as the New Cornerstone Investigator in the Chinese Mainland by the New Cornerstone Science Foundation in 2023. Her accolades include winning the Bank of China Hong Kong Science and Technology Innovation Prize in Life and Health in 2024, as well as The Visionary Women Award in the same year. She was bestowed with the Croucher Professorship in Medical Sciences in 2022 and awarded the Ministry of Education (MoE) Higher Education Outstanding Scientific Research Output Awards (Natural Science), First-class award in 2020. As a successful clinician-entrepreneur, she was recognised with the Best Innopreneur Award by the Federation of Hong Kong Industries in 2025 and received the Technology Fast Outstanding Female Entrepreneur Award by Deloitte Hong Kong in 2022.

As a world-leading IBD pioneer, Prof. Ng is the Truelove Lecturer at the University of Oxford in 2026. She was awarded Joanna and David Sachar International Award and Visiting Professorship (Mount Sinai, New York) and Sir Francis Avery Jones Award and Visiting Professorship (St Mark’s Hospital, London) in 2019, Cleveland Clinic IBD Global Visiting Professorship in 2021, and World Gastroenterology Organization (WGO) Distinguished Global Lecture Award, by the Asian Pacific Digestive Week (APDW) in 2023.

1. Member of Hong Kong Academy of Sciences, The Hong Kong Academy of Sciences (ASHK) (2025)
2. Best Innopreneur Award, FHKI x OCBC Hong Kong Innopreneur Awards 2025, Federation of Hong Kong Industries and OCBC Hong Kong (2025)
3. Highly Cited Researchers, Clarivate (2020 – 2025)
4. World’s Top 2% Scientists List, Stanford University and Elsevier (2020 – 2025)
5. The Visionary Women Awards 2024, Harper’s BAZAAR Hong Kong, South China Morning Post (2025)
6. Bank of China Hong Kong Science and Technology Innovation Prize (STIP) in Life and Health, Hong Kong Alliance of Technology and Innovation (HKATI) (2024)
7. Foreign Member of Academia Europaea 2024, Clinical & Veterinary Science Section, Academia Europaea (2024)
8. New Cornerstone Investigator, New Cornerstone Investigator Program in Biology and Biomedical Sciences, New Cornerstone Science Foundation (2023)
9. Croucher Professor in Medical Sciences, Croucher Foundation (2022)
10. 國家教育部高等學校科學研究優秀成果獎 (自然科學獎一等獎) (First-class Ministry of Education (MOE) Higher Education Outstanding Scientific Research Output Award (Natural Science Award)) on Integrative Research on Epidemiology, Pathogenesis and Therapeutics in IBD, Ministry of Education of the People’s Republic of China (2020)

1. Hracs L, Windsor JW, Gorospe J, Cummings M, Coward S, Buie MJ, Quan J, Goddard Q, Caplan L, Markovinović A, Williamson T, Abbey Y, Abdullah M, Abreu MT, Ahuja V, Raja Ali RA, Altuwaijri M, Balderramo D, Banerjee R, Benchimol EI, Kaplan GG, et al. Global evolution of inflammatory bowel disease across epidemiologic stages. Nature. 2025;642(8067):458-466. doi:10.1038/s41586-025-08940-0.
2. Zheng J, Sun Q, Zhang M, Liu C, Su Q, Zhang L, Xu Z, Lu W, Ching J, Tang W, Cheung CP, Hamilton AL, Wilson O’Brien AL, Wei SC, Bernstein CN, Rubin DT, Chang EB, Morrison M, Kamm MA, Chan FKL, Zhang J, Ng SC. Noninvasive, microbiome-based diagnosis of inflammatory bowel disease. Nature Medicine. 2024;30(12):3555-3567. doi:10.1038/s41591-024-03280-4.
3. Lau RI, Su Q, Lau ISF, Ching JYL, Wong MCS, Lau LHS, Tun HM, Mok CKP, Chau SWH, Tse YK, Cheung CP, Li MKT, Yeung GTY, Cheong PK, Chan FKL, Ng SC. A synbiotic preparation (SIM01) for post-acute COVID-19 syndrome in Hong Kong (RECOVERY): A randomised, double-blind, placebo-controlled trial. Lancet Infectious Diseases. 2024;24(3):256-265. doi:10.1016/s1473-3099(23)00685-0.
4. Su Q, Lau RI, Liu Q, Li MKT, Yan Mak JW, Lu W, Lau ISF, Lau LHS, Yeung GTY, Cheung CP, Tang W, Liu C, Ching JYL, Cheong PK, Chan FKL, Ng SC. The gut microbiome associates with phenotypic manifestations of post-acute COVID-19 syndrome. Cell Host Microbe. 2024;32(5):651-660.e4. doi:10.1016/j.chom.2024.04.005.
5. Su Q, Wong OWH, Lu W, Wan Y, Zhang L, Xu W, Li MKT, Liu C, Cheung CP, Ching JYL, Cheong PK, Leung TF, Chan S, Leung P, Chan FKL, Ng SC. Multikingdom and functional gut microbiota markers for autism spectrum disorder. Nature Microbiology. 2024;9(9):2344-2355. doi:10.1038/s41564-024-01739-1.
6. Yau YK, Lau LHS, Lui RNS, Wong SH, Guo CL, Mak JWY, Ching JYL, Ip M, Kamm MA, Rubin DT, Chan PKS, Chan FKL, Ng SC. Long-term safety outcomes of fecal microbiota transplantation: Real-world data over 8 years from the Hong Kong FMT Registry. Clinical Gastroenterology and Hepatology. 2024;22(3):611-620.e12. doi:10.1016/j.cgh.2023.09.001.
7. Kobayashi T, Hibi T. Publisher correction: Gut microbiota in COVID-19: Key microbial changes, potential mechanisms and clinical applications. Nature Reviews Gastroenterology & Hepatology. 2023;20(3):195. doi:10.1038/s41575-023-00742-x;kwrd. (Correction)
8. Chan FKL, Wong MCS, Chan AT, East JE, Chiu HM, Makharia GK, Weller D, Ooi CJ, Limsrivilai J, Saito Y, Hang D v., Emery JD, Makmun D, Wu K, Ali RAR, Ng SC. Joint Asian Pacific Association of Gastroenterology (APAGE) – Asian Pacific Society of Digestive Endoscopy (APSDE) clinical practice guidelines on the use of non-invasive biomarkers for diagnosis of colorectal neoplasia. Gut. 2023;72(7):1240-1254. doi:10.1136/gutjnl-2023-329429.
9. Liu Q, Mak JWY, Su Q, Yeoh YK, Lui GCY, Ng SSS, Zhang F, Li AYL, Lu W, Hui DSC, Chan PK, Chan FKL, Ng SC. Gut microbiota dynamics in a prospective cohort of patients with post-acute COVID-19 syndrome. Gut. 2022;71(3):544-552. doi:10.1136/gutjnl-2021-325989.
10. Ng SC, Xu Z, Mak JWY, Yang K, Liu Q, Zuo T, Tang W, Lau L, Lui RN, Wong SH, Tse YK, Li AYL, Cheung K, Ching JYL, Wong VWS, Kong APS, Ma RCW, Chow EYK, Wong SKH, Ho ICH, Chan PKS, Chan FKL. Microbiota engraftment after faecal microbiota transplantation in obese subjects with type 2 diabetes: A 24-week, double-blind, randomised controlled trial. Gut. 2022;71(4):716-723. doi:10.1136/gutjnl-2020-323617.
11. Liu Q, Su Q, Zhang F, Tun HM, Mak JWY, Lui GCY, Ng SSS, Ching JYL, Li A, Lu W, Liu C, Cheung CP, Hui DSC, Chan PKS, Chan FKL, Ng SC. Multi-kingdom gut microbiota analyses define COVID-19 severity and post-acute COVID-19 syndrome. Nature Communications. 2022;13(1):6806-. doi:10.1038/s41467-022-34535-8.
12. Yang K, Niu J, Zuo T, Sun Y, Xu Z, Tang W, Liu Q, Zhang J, Ng EKW, Wong SKH, Yeoh YK, Chan PKS, Chan FKL, Miao Y, Ng SC. Alterations in the gut virome in obesity and type 2 diabetes mellitus. Gastroenterology. 2021;161(4):1257-1269.e13. doi:10.1053/j.gastro.2021.06.056.
13. Zhang J, Hoedt EC, Liu Q, Berendsen E, Teh JJ, Hamilton A, O’ Brien AW, Ching JYL, Wei H, Yang K, Xu Z, Wong SH, Mak JWY, Sung JJY, Morrison M, Yu J, Kamm MA, Ng SC. Elucidation of Proteus mirabilis as a key bacterium in Crohn’s disease inflammation. Gastroenterology. 2021;160(1):317-330.e11. doi:10.1053/j.gastro.2020.09.036.
14. Yeoh YK, Zuo T, Lui GCY, Zhang F, Liu Q, Li AYL, Chung ACK, Cheung CP, Tso EYK, Fung KSC, Chan V, Ling L, Joynt G, Hui DSC, Chow KM, Ng SSS, Li TCM, Ng RWY, Yip TCF, Wong GLH, Chan FKL, Wong CK, Chan PKS, Ng SC. Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID-19. Gut. 2021;70(4):698-706. doi:10.1136/gutjnl-2020-323020.
15. Zhang F, Zuo T, Yeoh YK, Cheng FWT, Liu Q, Tang W, Cheung KCY, Yang K, Cheung CP, Mo CC, Hui M, Chan FKL, Li CK, Chan PKS, Ng SC. Longitudinal dynamics of gut bacteriome, mycobiome and virome after fecal microbiota transplantation in graft-versus-host disease. Nature Communications. 2021;12(1):65-. doi:10.1038/s41467-020-20240-x.
16. Zuo T, Zhang F, Lui GCY, Yeoh YK, Li AYL, Zhan H, Wan Y, Chung ACK, Cheung CP, Chen N, Lai CKC, Chen Z, Tso EYK, Fung KSC, Chan V, Ling L, Joynt G, Hui DSC, Chan FKL, Chan PKS, Ng SC. Alterations in gut microbiota of patients with COVID-19 during time of hospitalization. Gastroenterology. 2020;159(3):944-955.e8. doi:10.1053/j.gastro.2020.05.048.
17. Ng SC, Kamm MA, Yeoh YK, Chan PKS, Zuo T, Tang W, Sood A, Andoh A, Ohmiya N, Zhou Y, Ooi CJ, Mahachai V, Wu CY, Zhang F, Sugano K, Chan FKL. Scientific frontiers in faecal microbiota transplantation: Joint document of Asia-Pacific Association of Gastroenterology (APAGE) and Asia-Pacific Society for Digestive Endoscopy (APSDE). Gut. 2020;69(1):83-91. doi:10.1136/gutjnl-2019-319407.
18. Zuo T, Sun Y, Wan Y, Yeoh YK, Zhang F, Cheung CP, Chen N, Luo J, Wang W, Sung JJY, Chan PKS, Wang K, Chan FKL, Miao Y, Ng SC. Human-gut-DNA virome variations across geography, ethnicity, and urbanization. Cell Host Microbe.2020;28(5):741-751.e4. doi:10.1016/j.chom.2020.08.005.
19. Ng SC, Shi HY, Hamidi N, Underwood FE, Tang W, Benchimol EI, Panaccione R, Ghosh S, Wu JCY, Chan FKL, Sung JJY, Kaplan GG. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: A systematic review of population-based studies. The Lancet. 2017;390(10114):2769-2778. doi:10.1016/s0140-6736(17)32448-0.
20. Ng SC, Tang W, Leong RW, Chen M, Ko Y, Studd C, Niewiadomski O, Bell S, Kamm MA, de Silva HJ, Kasturiratne A, Senanayake YU, Ooi CJ, Ling KL, Ong D, Goh KL, Hilmi I, Ouyang Q, Wang YF, Hu PJ, Zhu Z, Zeng Z, Wu K, Wang X, Xia B, Li J, Pisespongsa P, Manatsathit S, Aniwan S, Simadibrata M, Abdullah M, Tsang SWC, Wong TC, Hui AJ, Chow CM, Yu HH, Li MF, Ng KK, Ching J, Wu JCY, Chan FKL, Sung JJY. Environmental risk factors in inflammatory bowel disease: A population-based case-control study in Asia-Pacific. Gut. 2015;64(7):1063-1071. doi:10.1136/gutjnl-2014-307410.